<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717818</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02167</org_study_id>
    <nct_id>NCT03717818</nct_id>
  </id_info>
  <brief_title>Mechanisms of Change in Brief Treatment for Borderline Personality Disorder</brief_title>
  <acronym>BPDCHANGE</acronym>
  <official_title>Mechanisms of Change in Brief Treatment for Borderline Personality Disorder: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present two-arm randomized controlled study aims at testing the effects (i.e., symptom
      reduction) and the underlying mechanisms of change associated with a brief psychiatric
      treatment (10 sessions over 4 months), compared with treatment as usual. Participants undergo
      assessments at four points (intake, 2 months, discharge and 12 month follow-up). In addition
      to symptom measures, all individuals undergo a two-step assessment for the potential
      mechanisms of change (i.e., emotion and socio-cognitive processing): a) behavioural and b)
      neurofunctional. We hypothesize that change in the mechanisms explains the treatment effects.
      The present study uses an innovative treatment of BPD and at the same time a sophisticated
      assessment procedure to demonstrate the critical role of psychobiological change in emotion
      and sociocognitive processing in brief treatments. It will help increase the effectiveness of
      initial treatment phase for BPD and help diminish the societal burden of disease related with
      BPD. This study is funded by the Swiss National Science Foundation (SNSF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ZAN-BPD (Zanarini Borderline Personality Disorder Scale; Zanarini, 2003)</measure>
    <time_frame>4 months</time_frame>
    <description>measures borderline symptomatology from an dimensional perspective, ranges between 0 and 36 (36 being the most symptomatic), global score (sum of all 9 items coded between 0 and 4) used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OQ-45 (Outcome Questionnaire-45.2, Lambert et al., 2004)</measure>
    <time_frame>4 months</time_frame>
    <description>measures the level of problems (distress, social and interpersonal) on a scale ranging from 0 to 180 (45 items coded between 0 and 4, 4 being the most symptomatic). A total sum score will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSL-23 (Borderline Symptom List, Short Version; Bohus et al., 2009)</measure>
    <time_frame>4 months</time_frame>
    <description>measures the intensity of borderline symptoms using a mean score of the 23 items ranging between 0 and 4 (4 being the most symptomatic), the mean score will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Good Psychiatric Management-Brief</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual-Brief</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Good Psychiatric Management - Brief</intervention_name>
    <description>specific interventions as defined by Gunderson and Links (2014)</description>
    <arm_group_label>Good Psychiatric Management-Brief</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>treatment as usual</intervention_name>
    <description>non-specific intervention</description>
    <arm_group_label>Treatment as Usual-Brief</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Borderline Personality Disorder

          -  age between 18 and 35

        Exclusion Criteria:

          -  non-mastery in French

          -  neurological disorders

          -  schizophrenia (according to DSM-5)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry-CHUV, University of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1003</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ueli Kramer, PhD PD</last_name>
      <phone>+41 21 314 00 50</phone>
      <email>ueli.kramer@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Kramer U, Kolly S, Maillard P, Pascual-Leone A, Samson AC, Schmitt R, Bernini A, Allenbach G, Charbon P, de Roten Y, Conus P, Despland JN, Draganski B. Change in Emotional and Theory of Mind Processing in Borderline Personality Disorder: A Pilot Study. J Nerv Ment Dis. 2018 Dec;206(12):935-943. doi: 10.1097/NMD.0000000000000905.</citation>
    <PMID>30507735</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Ueli Kramer</investigator_full_name>
    <investigator_title>PD Dr. phil. Head of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

